ISMICS Home  |  2022 Scientific Annual Meeting  |  Past & Future Meetings
International Society For Minimally Invasive Cardiothoracic Surgery

Back to 2021 ePosters


Contemporary Outcomes of Temporary Percutaneous Right Ventricular Support in a Heterogeneous Right Ventricular Failure Cohort
Danny Ramzy, Mark Kearns, Laurance Czer
Cedars-Sinai Medical Center, Los Angeles, CA, USA

Background Right ventricular failure occurs in a variety of clinical settings and is associated with reduced survival. We sought to describe our recent clinical experience with two temporary percutaneous right ventricular assist devices (RVAD): TandemLife Protek Duo (TPD; TandemLife Pittsburg, PA) and the Impella RP (Abiomed, Danvers, MA). Methods A prospectively collected institutional heart failure device registry was mined for clinical data related to TPD and Impella RP devices. Baseline demographic characteristics, etiology of heart failure, indication for RVAD support, and timing of implantation in relation to onset of right ventricular (RV) failure were characterized for both temporary percutaneous RVADs. Specific clinical outcomes, including overall survival, time on temporary support, device explant and device exchanges were analyzed. Outcomes were further analyzed among the cohort explanted patients. Results Between 2015-2018 19 TPD devices and 10 impella RP devices were implanted. Indication for RV support included post-left ventricular assist device (LVAD) implantation RV failure, post-cardiotomy cardiogenic shock, and post-transplant (TPx) RV failure. Mean(median) device support duration for TPD was 16(12) days, and 5(4) days for Impella RP. Among TPD patients, 11(57.9%) were explanted, 4 (21%) died, and there were no device exchanges. Among the Impella RP patients, 5(50%) were explanted and 3(30%) died, and 1 (10%) required device exchange. Among the TPD patient explanted 7(63.6%) recover and were weaned, 3(27.2%) died, and 1(9.1%) required a durable RVAD. Among the Impella RP patient explanted 4(80%) recover and were weaned 1(20%) required a durable RVAD. Conclusions RV failure, commonly encountered in surgical heart failure patient, is associated with reduced survival. Temporary percutaneous RVAD devices provide an attractive means of bridging to RV recovery. It appears that regardless of RVAD type, percutaneous mechanical support of the RV improves survival.


Back to 2021 ePosters

By using this site, you agree to our updated Privacy Policy.  Got it